Skip to main content
Log in

Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

High sensitivity C-reactive protein (hs-CRP) is synthesized mainly by hepatocytes in response to tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). The interaction of advanced glycation end products (AGEs) with the receptor for advanced glycation end products (RAGE) increases the expression of the cytokines TNF-α, IL-1, and IL-6. Soluble receptor for advanced glycation end products (sRAGE) competes with RAGE for binding with AGEs. Hence, low sRAGE levels may increase interaction of AGEs with RAGE resulting in the increased production of cytokines. It is hypothesized that serum levels of sRAGE modulate serum levels of hs-CRP. The objectives are to determine if (i) serum levels of sRAGE are lower and those of TNF-α and hs-CRP are higher in non-ST-segment elevation myocardial infarction (NSTEMI) patients compared to control subjects; (ii) serum levels of TNF-α and hs-CRP are positively correlated; and (iii) sRAGE is negatively correlated with hs-CRP and TNF-α. The study consisted of 36 patients with NSTEMI and 30 age-matched healthy male subjects. Serum levels of sRAGE and TNF-α were determined by enzyme-linked immunoassay and hs-CRP was measured using near infrared immunoassay. Serum levels of sRAGE were lower, while those of TNF-α and hs-CRP were higher in patients with NSTEMI compared to controls. The levels of sRAGE were negatively correlated with those of TNF-α and hs-CRP, while TNF-α was positively correlated with hs-CRP in both the control subjects and NSTEMI patients. The data suggest that sRAGE modulates the synthesis of hs-CRP through TNF-α.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ridker PM, Silvertown JD (2008) Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 79:1544–1551

    Article  CAS  PubMed  Google Scholar 

  2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1998) Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97:425–428

    CAS  PubMed  Google Scholar 

  3. Prasad K (2003) C-reactive protein and cardiovascular disease. Int J Angiol 12:1–9

    Article  CAS  Google Scholar 

  4. Meuwissen M, van der Wal AC, Niessen HW, Koch KT, de Winter RJ, van der Loos CM, Rittersma SZ, Chamuleau SA, Tijssen JG, Becker AE, Piek JJ (2006) Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol 59:196–201

    Article  CAS  PubMed  Google Scholar 

  5. Hurlimann J, Thorbecke G, Hochwald GM (1966) The liver as the site of C-reactive protein formation. J Exp Med 123:365–378

    Article  CAS  PubMed  Google Scholar 

  6. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I (1991) Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 146:3032–3037

    CAS  PubMed  Google Scholar 

  7. Neumann A, Schinzel R, Palm D, Reiderer P, Münch G (1999) High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett 453:283–287

    Article  CAS  PubMed  Google Scholar 

  8. Geroldi D, Falcone C, Emanuele E (2006) Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 13:1971–1978

    Article  CAS  PubMed  Google Scholar 

  9. Prasad K (2006) Soluble receptors for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 15:57–68

    CAS  Google Scholar 

  10. Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25:1032–1037

    Article  CAS  PubMed  Google Scholar 

  11. Theroux P, Armstrong P, Mahaffey K, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB (2005) Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a sub-study of the COMMA trial. Eur Heart J 26:1964–1970

    Article  PubMed  Google Scholar 

  12. Antonicelli R, Olivieri F, Cavallone L, Spazzafumo L, Bonafè M, Marchegiani F, Cardelli M, Galeazzi R, Giovagnetti S, Perna GP, Franceschi C (2005) Tumor necrosis factor-alpha gene 308G > A polymorphism is associated with ST-elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. Coron Artery Dis 16:489–493

    Article  PubMed  Google Scholar 

  13. del Fresno C, Soler-Rangel L, Soares-Schanoski A, Gómez-Piña V, González-León MC, Gómez-García L, Mendoza-Barberá E, Rodríguez-Rojas A, García F, Fuentes-Prior P, Arnalich F, López-Collazo E (2007) Inflammatory responses associated with acute coronary syndrome up-regulate IRAK-M and induce endotoxin tolerance in circulating monocytes. J Endotoxin Res 13:39–52

    Article  PubMed  Google Scholar 

  14. di Stefano R, di Bello V, Barsotti MC, Grigoratos C, Armani C, Dell’Omodarme M, Carpi A, Balbarini A (2009) Inflammatory markers and cardiac function in acute coronary syndrome: difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models. Biomed Pharmacother 63:773–780

    Article  CAS  PubMed  Google Scholar 

  15. Mulvihill NT, Foley JB (2002) Inflammation in acute coronary syndromes. Heart 87:201–204

    Article  CAS  PubMed  Google Scholar 

  16. Wang YN, Che SM, Ma AQ (2004) Clinical significance of serum cytokines IL-1beta, sIL-2R, IL-6, TNF-alpha and IFN-υ in acute coronary syndrome. Chin Med Sci J 19:120–124

    CAS  PubMed  Google Scholar 

  17. Giansante C, Fiotti N, Di Chiara A, Altamura N, Wasserman S, Fioretti P, Guarnieri G (2007) In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers. J Cardiovasc Med 8:602–607

    Google Scholar 

  18. Sentürk T, Cordan J, Baran I, Ozdemir B, Güllülü S, Aydinlar A, Göral G (2007) Procalcitonin in patients with acute coronary syndrome: correlation with high-sensitivity C-reactive protein, prognosis and severity of coronary artery disease. Acta Cardiol 62:135–141

    Article  PubMed  Google Scholar 

  19. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald E, Thrombolysis in myocardial infarction (TIMI) Study Group (2007) Clinical application of C-reactive protein across the pectrum of acute coronary syndromes. Clin Chem 53:1800–1807

    Article  CAS  PubMed  Google Scholar 

  20. Blake GJ, Ridker PM (2003) C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 41:37S–42S

    Article  CAS  PubMed  Google Scholar 

  21. James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, Simoons ML, Topol EJ, Venge P, Wallentin L, GUSTO-IV-ACS Investigators (2003) Troponin and C-reactive have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a Gusto-IV substudy. J Am Coll Cardiol 41:916–924

    Article  CAS  PubMed  Google Scholar 

  22. Irfan G, Ahmad M (2008) Highly sensitive C-reactive protein concentration and angiographic characteristics of coronary lesion. J Ayub Med Coll Abbottabad 20:100–103

    PubMed  Google Scholar 

  23. Schmidt AM, Hori O, Chen JX, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395–1403

    Article  CAS  PubMed  Google Scholar 

  24. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D (1993) Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 91:2155–2168

    Article  CAS  PubMed  Google Scholar 

  25. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889–901

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This manuscript forms part of the PhD thesis of Dr. Erick D. McNair. This work was supported by grants from the Heart and Stroke Foundation of Saskatchewan and the Pollack Research Foundation of Saskatchewan. The authors acknowledge the assistance of Ms. Heather Neufeld in biochemical measurements and Ms. Barbara Raney with the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kailash Prasad.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McNair, E.D., Wells, C.R., Mabood Qureshi, A. et al. Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Mol Cell Biochem 341, 135–138 (2010). https://doi.org/10.1007/s11010-010-0444-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-010-0444-3

Keywords

Navigation